SCHEMBL5426893

SCHEMBL5426893

CCN(CC)C(=O)c1cncc(-c2ccoc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 8/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ ABL1 P00519 2/20 0.40
▸ BCR P11274 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39
▸ ADORA2A P29274 2/20 0.39
▸ ADORA1 P30542 2/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2B P29275 1/20 0.39
▸ LMNA P02545 3/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSP90AA1 P07900 2/20 0.38
▸ HSP90AB1 P08238 2/20 0.38
▸ CPT2 P23786 1/20 0.38
▸ CPT1A P50416 1/20 0.38
▸ HDAC1 Q13547 1/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5424646 0.80 HPGD (0.47) HPGDALDH1A1ABL1BCRMAPT
SCHEMBL1315565 0.78 MKNK1 (0.55) ALDH1A1LMNAHDAC1MEN1KMT2A
SCHEMBL5430302 0.78 HPGD (0.49) HPGDALDH1A1ABL1BCRMAPT
SCHEMBL5437021 0.78 SCN10A (0.52) HPGDALDH1A1ABL1BCRMAPT
SCHEMBL5422107 0.78 MKNK1 (0.58) HPGDALDH1A1ABL1BCRMAPT
SCHEMBL27986640 0.78 HPGD (0.56) HPGDALDH1A1ABL1BCRMAPT
SCHEMBL5419503 0.77 HPGD (0.47) HPGDALDH1A1ABL1BCRMAPT
SCHEMBL1315420 0.76 CYP11B2 (0.56) ALDH1A1ADORA2AADORA3ADORA2BHDAC1
SCHEMBL5424848 0.76 HPGD (0.67) HPGDALDH1A1ABL1BCRMAPT
SCHEMBL5429432 0.75 HPGD (0.49) HPGDALDH1A1ABL1BCRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 — — US claimed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 — — US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 — — WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 — — US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 — — US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 — — US disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 — — US disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 — — WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 HPGD 158/4885ALDH1A1 837/4885ABL1 660/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 HPGD 158/4885ALDH1A1 837/4885ABL1 660/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 HPGD 149/4885ALDH1A1 450/4885ABL1 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback